

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 August 2003 (07.08.2003)

PCT

(10) International Publication Number
WO 03/064460 A2

(51) International Patent Classification⁷: **C07K 7/23**

(21) International Application Number: PCT/IN03/00015

(22) International Filing Date: 10 January 2003 (10.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/353,041 30 January 2002 (30.01.2002) US

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH** [IN/IN]; Rafi Marg, 110 001 New Delhi (IN).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **CHATTERJEE, Abhijit** [IN/IN]; Visa-Bharati University, Santiniketan, 731 235 West Bengal (IN). **RAY, Partha** [IN/IN]; Visva-Bharati University, Santiniketan, 731 235 West Bengal (IN). **DASGUPTA, Subrata** [IN/IN]; Visva-Bharati University, Santiniketan, 731 235 West Bengal (IN). **BHATTACHARAYA, Samir** [IN/IN]; Indian Institute of Chemical Biology, 4, Raja S.C. Mullick Road, 700 032 Kolkata (IN). **PASHA, Santosh** [IN/IN]; Central for Biochemical Technology, Mall Road, 110 009 Delhi (IN).

(74) Agent: **BHOLA, Ravi**; KUMARAN & SAGAR, 84-C, C6 LANE, OFF CENTRAL AVENUE, SAINIK FARMS, 110 062 NEW DELHI (IN).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

Declaration under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL TWO GONADOTROPIN RELEASING HORMONES AND A METHOD TO ISOLATE THE SAME

(57) Abstract: The present invention relates to two novel Gonadotropin releasing hormones muGnRH I and muGnRH II of amino acid SEQ ID 1 as QHWSAWRLPG, and SEQ ID 2 QHWSWGILPG respectively, useful for induced breeding in fish both in combination and alone, by activating production of Gonadotropin, and a method of isolating the same from Indian Murrel brain, and further, a method of inducing breeding in fishes using the said novel gonadotropin releasing hormones.



WO 03/064460 A2

NOVEL TWO GONADOTROPIN RELEASING HORMONES AND A METHOD TO ISOLATE THE SAME

Technical Field

5 The present invention relates to two novel Gonadotropin releasing hormones muGnRH I and muGnRH II of amino acid SEQ ID 1 as QHWSAWRLPG, and SEQ ID 2 QHWSWGILPG respectively, useful for induced breeding in fish both in combination and alone, by activating production of Gonadotropin, and a method of isolating the same from Indian Murrel brain, and further, a method of inducing breeding in fishes using the said
10 novel gonadotropin releasing hormones.

Background Art

Gonadotropin Releasing Hormone (GnRH) is now the best available biotechnological tool for the induced breeding of fish. GnRH is the key regulator and central initiator of reproductive cascade in all vertebrates.

15 It's a decapeptide and first isolated from pig and sheep hypothalami with the ability to induce pituitary release of luteinising hormone (LH) and follicle stimulating hormone (FSH). Since then only one form of GnRH has been identified in most placenta! mammals including human beings as the sole neuropeptide causing the release of LH and FSH.

However, in non-mammalian species (except guinea pig) twelve GnRH variants have now
20 been structurally elucidated, among them seven different forms have been isolated from fish species. Depending on the structural variants and their biological activities number of chemical analogues have been prepared and one of them is sahnnon GnRH analogue profusely used now in fish breeding and marketed commercially throughout the world. Question is why fishes require an induction by this neuropeptide hormone to release germ cells from
25 male and female partners so that fertilization of oocytes by sperms may occur in the aquatic ambience.

In fact, most of the economically important culturable fish in land-locked water do not breed until they are induced by the hormone. Fish in marine or riverine water do not need induction by hormone for their breeding. But to culture fish with the intention of increasing
30 the yield of production in either ocean or river is not possible. Culture requires a controllable area, that's why pisciculture to enhance the yield is restricted to land-locked aquatic bodies where fish do not usually breed or spawn without the induction of hormone.

Since fish meat has been found to be the best quality food among all animal meats, there is an enormous increase in fish producing industries in global scenario recently where the major

rate-limiting factor is breeding. The induced breeding of fish is now successfully achieved by the development of GnRH technology. In this overview, a brief description is given to conceive the biotechnology of this highly important area of our food supplement.

Structure of GnRH - GnRH was first isolated from the mammalian hypothalamus as a decapeptide (Burgus et al., 1972; Mastuo et al., 1971). Since then, several structural variants of GnRH have been described which can be seen in Fig. 1 (shown under the heading brief description of accompanying drawings).

There has been a striking conservation in GnRH peptide length, the first four -NH₂ terminus and two -COOH terminus amino acids are remarkably conserved in different vertebrates.

Whatever changes occurred are between 5 and 8 amino acid residues, position 8 is most variable followed by position 6, 5 and 7. This highly variable position 8 suggests its role in the variation of biological activity between the species and its critical function in recognizing GnRH receptors on the pituitary cell membrane. To exert its biological function it has to first recognize its receptor on the pituitary gonadotroph cell membrane and when it has to do so its linear structure changes into a loop. The NH₂- and COOH-terminal domain of GnRH are closely opposed when GnRH binds to its receptor and this is the proposed result from a P-II type turn involving residues 5-8. The P turn creates a hairpin loop that aligns N and C termini (Sealfon et al., 1997) (Fig-2). (Shown under the heading brief description of accompanying drawings).

GnRH from Indian fish - Although India has several varieties of indigenous culturable bony fish, practically nothing is known about their GnRH. This is really a very unfortunate situation for which we still have to depend on the supply from other countries to investigate the reproductive biology of our economically important culturable fish as GnRH is the key regulator of reproductive control mechanism.

Several years ago we initiated this research and faced serious problems. For the isolation of this peptide we would need an assay system to identify the desired molecule at each step of purification. First piscine GnRH isolated purified and structure determined was Salmon GnRH (Sherwood and her associates in 1983), and the most current GnRH purified and characterized by two different groups Carolsfeld *et al* and Robinson *et al.*, was in 2000. Between the span of this time, number of GnRH variants have been isolated by depending on the immunoreactivity of this molecule. During Salmon GnRH isolation, Sherwood et al took the help of anti-GnRH antibody from mammalian source, later they developed Salmon anti-GnRH antibody which permitted to isolate different GnRH forms from other sources.

Meanwhile Jamaluddin *et al*, (Gen comp Endocrinology 1989 May; 74(2): 190-8) of applicants laboratory developed a very dependable GnRH bioassay. Basic principle of this bioassay is to get the release of GTH from murrel primary pituitary cell culture and determine the amount of GTH released by GTH -RIA.

5 **Objects of the Present invention**

The main object of the present invention is to isolate and identify novel gonadotropin releasing hormones for induced breeding in fishes.

Another main object of the present invention is to develop a method of isolating and sequencing novel gonadotropin releasing hormones from Indian Murrel brain.

10 Yet another object of the present invention is to develop gonadotropin-releasing hormones for enhanced release of gonadotropin in fishes.

Still another object of the present invention is to develop gonadotropin-releasing hormones showing synergistic effect.

15 Still another object of the present invention is to develop various fractions of hypothalami with gonadotropin releasing hormone activity.

Still another object of the present invention is to determine the effect of calcium on the gonadotropin hormone releasing activity of GnRH.

Still another embodiment of the present invention is to develop a method of inducing breeding in fishes using the said novel gonadotropin releasing hormones.

20 **Summary of the present invention**

The present invention relates to two novel Gonadotropin releasing hormones muGnRH I and muGnRH II of amino acid SEQ ID 1 as QHWSAWRLPG, and SEQ ID 2 QHWSWGILPG respectively, useful for induced breeding in fish both in combination and alone, by activating production of Gonadotropin, and a method of isolating the same from
25 Indian Murrel brain, and further, a method of inducing breeding in fishes using the said novel gonadotropin releasing hormones.

Detailed description of the present invention

Accordingly, the present invention relates to two novel Gonadotropin releasing hormones muGnRH I and muGnRH II of amino acid SEQ ID 1 as QHWSAWRLPG, and SEQ ID 2
30 QHWSWGILPG respectively, useful for induced breeding in fish both in combination and alone, by activating production of Gonadotropin, and a method of isolating the same from Indian Murrel brain, and further, a method of inducing breeding in fishes using the said novel gonadotropin releasing hormones.

Further, the present invention relates to two novel Gonadotropin releasing hormones muGnRH I and muGnRH II of amino acid sequence QHWSAWRLPG and QHWSWGILPG respectively, useful for induced breeding in fishes both in combination and alone, by activating production of Gonadotropin.

5 In an embodiment of the present invention, said hormones are obtained from Indian Murrel brain.

In another embodiment of the present invention, muGnRH II is a more active gonadotropin releasing hormone than muGnRH I.

10 In yet another embodiment of the present invention, muGnRH I increase gonadotropin release by about 30 times.

In still another embodiment of the present invention, muGnRH II increase gonadotropin release by about 35 times.

15 In still another embodiment of the present invention, wherein both muGnRH I, and muGnRH II in combination in the ratio of about 1:1 increase gonadotropin release by about 50 times.

In still another embodiment of the present invention, said hormones show synergy in induced breeding of fishes.

In still another embodiment of the present invention, both muGnRH I and muGnRH II in combination increase gonadotropin release by about 50 times.

20 In still another embodiment of the present invention, said hormones show no species barrier in induced breeding of fishes with increase in gonadotropin release ranging between 20-50 times.

25 In still another embodiment of the present invention, said hormones are more active than other GnRHs comprising mammalian GnRH, Salmon GnRH, GnRH superactive analogues, and commercially available GnRH Ovaprim, both in combination and alone.

In an embodiment of the present invention, a method of isolating and sequencing two novel Gonadotropin releasing hormones muGnRH I and muGnRH II of amino acid sequence QHWSAWRLPG and QHWSWGILPG respectively, useful for induced breeding in fishes both in combination and alone, by activating production of Gonadotropin.

30 In another embodiment of the present invention, homogenizing hypothalami in acidic conditions.

In yet another embodiment of the present invention, filtering said homogenate to remove fat and cell debris.

In still another embodiment of the present invention, adding acetone in a stepwise manner to the said filtrate to obtain three precipitates namely AC I, AC II, and AC III.

In still another embodiment of the present invention, estimating Gonadotropin Releasing Hormone (GnRH) activity in the said precipitates.

- 5 In still another embodiment of the present invention, fractionating only active precipitate AC II further using Molecular Exclusion Chromatography to obtain fractions SG I and SG II.

In still another embodiment of the present invention, estimating Gonadotropin Releasing Hormone (GnRH) activity in the fractions of previous step.

- 10 In still another embodiment of the present invention, fractionating only active fraction SG II further, using Ion Exchange Chromatography with anionic column to collect fractions MQ I, MQ II, MQ III, and MQ IV.

In still another embodiment of the present invention, estimating Gonadotropin Releasing Hormone (GnRH) activity in the fractions of previous step, with only fractions MQ I and

- 15 MQ II having the same.

In still another embodiment of the present invention, fractionating MQ I further, using Ion Exchange Chromatography with cationic column to obtain fractions MS I, MS II, MS III, and MS IV.

- 20 In still another embodiment of the present invention, estimating Gonadotropin Releasing Hormone (GnRH) activity in the fractions of previous step with only fraction MS II having the same.

In still another embodiment of the present invention, fractionating MS II fraction using Reverse Phase Chromatography to obtain fractions SRP I, SRP II, and SRP III.

- 25 In still another embodiment of the present invention, estimating Gonadotropin Releasing Hormone (GnRH) activity in the fractions of previous step with only fraction SRP II having the same.

In still another embodiment of the present invention, fractionating MQ II further, using Reverse Phase Chromatography to obtain fractions QRP I, QRP II, and QRP III.

- 30 In still another embodiment of the present invention, calculating Gonadotropin Releasing Hormone (GnRH) activity in the fractions of previous step with only fraction QRP II having the same.

In still another embodiment of the present invention, sequencing QRP II and SRP II fractions of above-mentioned step and naming them as muGnRH I and muGnRH II respectively.

In still another embodiment of the present invention, wherein fraction SG II increase gonadotropin release by about 20 times.

In still another embodiment of the present invention, wherein fraction SG II increase gonadotropin release by about 20 times.

5 In still another embodiment of the present invention, wherein fraction MQ I increase gonadotropin release by about 10 times.

In still another embodiment of the present invention, wherein fraction MQ II increase gonadotropin release by about 40 times.

10 In still another embodiment of the present invention, wherein fraction MS II increase gonadotropin release by about 45 times.

In still another embodiment of the present invention, wherein calcium increase gonadotropin releasing activity of muGnRH I and II.

A method of inducing breeding in fishes using the said novel gonadotropin releasing hormones said method comprising steps of exposing fishes to the said Gonadotropin-releasing hormones to help release gonadotropin, and inducing breeding in fishes using
15 said gonadotropin.

Brief description of the accompanying drawings

Fig 1 shows comparison of primary amino acid sequences of naturally occurring vertebrates and protochordate GnRHs. Underlined amino acids represent differences in
20 forms compared to mammalian GnRH.

Fig 2 shows hairpin loop of GnRH.

Fig 3 shows test of murrel GnRH activity in different fractions obtained through acetone fraction. After preparation of three different fractions, 100micrograms protein was added *in vitro* pituitary cell culture and release of GtH was measured by RIA.

25 **Fig 4** shows elution profile of mammalian GnRH through Sephadex G-25 column. AC II fraction was dissolved in 1 N acetic acid and eluted through Sephadex G-25 column (58 × 1.5 cm) at a flow rate of 24 ml/hr.

Fig 5a shows elution profile of murrel Sephadex G-25 P-II through FPLC Mono Q column. SG II fraction was dissolved in buffer A-20mM Tris (pH 8.0) and was injected
30 into the FPLC anion exchange column (Mono Q). At first the column was washed with buffer A and then eluted with buffer B-20 mM Tris (pH 8.0) with 1M NaCl. **Fig 5b** shows elution profile of murrel Mono Q unbound peak (MQ I) through FPLC Mono S column. MQ I was dissolved in buffer A-50mM ammonium acetate (pH 4.8) and was injected into

the FPLC cation exchange column (Mono S). at first the column was washed with buffer A and then eluted with buffer B-50 mM Ammonium acetate(pH 4.8) with 0.5M NaCl.

Fig 6 shows elution profile of Mono QP-II (a) and Mono SP-II (b) through FPLC Pep-RPC column. GnRH enriched fraction (Mono QP-II) and (Mono SP-II) was dissolved individually in solvent A-0.1% TFA in water and was injected individually into the FPLC peptide reverse phase chromatography (Pep-RPC). Firstly the column was washed with solvent A and then eluted with solvent B-0.1% TFA in acetonitrile.

Fig 7 shows amino acid sequences of muGnRH I, and muGnRH II.

Purification of murrel GnRH

(i) Extraction and solvent fractionation:

The hypothalami were homogenized using 1 N acetic acid containing 1 mM PMSF in a Potter-Elvehjem homogenizer under ice. To avoid frothing, homogenization was done very cautiously and slowly. The pH of the crude homogenate was maintained at pH 3.2. The extracted material was filtered through double-fold cheesecloth to remove fat and cell debris.

It was then lyophilized and stored at -80°C until further use. The dried extract was reconstituted in 0.1 N acetic acid and equal volume of chilled acetone was added and kept at -20°C for 15 min.

A thick precipitate (AC I) appears at the bottom of the suspension while a clear supernatant is decanted off and to it double the volume of chilled acetone was added and kept at -20°C for 30 min following which another thin precipitate layer (AC II) appeared. Once again, the clear supernatant was decanted and double the volume of chilled acetone was added to it and kept at -20°C for 14h.

This resulted in the appearance of another thin precipitate layer (AC III) and further addition of chilled acetone to the clear supernatant did not result in the formation of any precipitate even after keeping it for 3 days at -20°C. These three acetone fractions were extracted with petroleum ether (40-60°C) to remove acetone, lipids and other hydrophobic substances.

The final precipitates were centrifuged at 8,000 g for 15 min at 4°C and the residues were stored at -80°C until further use. GnRH enriched fraction was identified as AC II on the basis of GTH release from pituitary cell culture in vitro (Fig. 3).

Molecular Exclusion chromatography:

GnRH was further purified by subjecting AC II to molecular exclusion chromatography on a Sephadex G 25 column. Elution of the column with 0.05 M PBS resulted in two distinct peaks, SG I and SG II (Fig. 4). Mammalian GnRH was consequently run to identify the

pattern on the column. On the basis of GtH release from pituitary cell incubation *in vitro*, GnRH was found to be located in SG II. As shown in table 1 below.

Table 1

Biological activities of Sephadex G-25 eluted fractions in terms of GtH release from murrel pituitary cell incubations

System [*]	GtH released (ng/6x10 ⁴ cells)
Control (C)	2.8 ± 0.18
C + SG I	9.3 ± 0.93
C + SG II	37.9 ± 2.18

(ii) *Ion exchange chromatography:*

This was further purified by FPLC Mono Q (anionic) and Mono S (cationic) ion-exchange chromatography. The pooled, dialysed and lyophilised active peak of the molecular exclusion chromatographic step (SG II) was loaded on a Mono Q column; washing the Mono Q column with 20 mM Tris (pH 8.0) gave rise to a unbound peak (MQ I) while on gradient elution with NaCl (1.0 M) containing 20 mM Tris (pH 8.0), three bound peaks (MQ II, MQ III and MQ IV) were obtained (Fig. 5a).

Assay of GnRH activity on the basis of GtH release from *in vitro* pituitary cell culture identified the bound MQ II to possess the maximum GnRH activity while MQ III and MQ IV showed negligible activity (As shown below in Table 2a).

Table 2a

Biological activities of FPLC Mono Q and Mono S eluted fractions in terms of GtH release from murrel pituitary cell incubations

System ^a	GtH released (ng/6x10 ⁴ cells)
Control (C)	2.5 ± 0.17
C + MQ I	21.6 ± 0.98
C + MQ II	77.5 ± 2.92
C + MQ III	2.7 ± 0.29
C + MQ IV	2.3 ± 0.34

^a 2 µg protein from each peak was added to the incubation systems. Values are mean ± SEM of four experiments

Surprisingly the unbound peak of the Mono Q elution (MQ I) also showed significant amounts of GnRH activity thus indicating the presence of a cationic form of GnRH.

MQ I was therefore loaded onto a Mono S (cationic) column; washing the column with 50 mM ammonium acetate (pH 4.8) gave rise to a single unbound peak (MS I) while on

subsequent gradient elution with 0.5 M NaCl, three bound peaks (MS II, MS III and MS IV) were obtained (Fig. 5b). Assay of GnRH activity in all the four peaks identified MS II to be highly enriched in GnRH (As shown below in table 2b).

Table 2b

System ^a	GtH released (ng/6x10 ⁴ cells)
Control (C)	2.4 ± 0.16
C + MS I	3.4 ± 0.23
C + MS II	83.1 ± 3.46
C + MS III	3.0 ± 0.18
C + MS IV	2.6 ± 0.09

5 ^a 2 µg protein from each peak was added to the incubation systems. Values are mean ± SEM of four experiments

(iii) Reverse Phase chromatography:

We now had two forms of GnRH in hand—one anionic form (MQ II) and the other cationic
10 form (MS II). Both were further purified through Pep-RPC column chromatography. After loading the column with either MQ II or MS n, in both the cases, the unbound proteins were eluted with 0.1% trifluoroacetic acid in water while the bound material was eluted with 0.1% trifluoroacetic acid in acetonitrile gradient. MQ II resolved into one unbound peak (QRP I) and two bound peaks (QRP H and QRP HI) (Fig. 6a); MS H gave rise to one unbound (SRP I) and
15 two bound (SRP II and SRP ID) peaks (Fig. 6b). GnRH was found to be located in QRP H and SRP H (Fig 6 insets) and were termed muGnRH I (anionic) and muGnRH H (cationic).

(iv) Functional activity of the purified GnRHs

Both muGnRH I and muGnRH II are highly active in releasing GTH from murrel pituitary cells, muGnRH II being slightly more active. Moreover, these two GnRHs act almost
20 equally in different species of carp indicating no species barrier (As shown below in Table 3).

Table 3

A comparison of gonadotropin release from the pituitaries of different carps in response to murrel GnRH I and II

Carp species	Incubations (2µg GnRH fractions)	GtH II released (ng/6x10 ⁴ cells)
<i>Catla catla</i>	Control (C)	2.6 ± 0.32
	C + mGnRH I	74.5 ± 2.32
	C + mGnRH II	82.6 ± 3.02*
<i>Cirrhinus mrigala</i>	Control (C)	2.1 ± 0.24
	C + mGnRH I	72.0 ± 2.13
	C + mGnRH II	80.1 ± 2.61*
<i>Cyprinus carpio</i>	Control (C)	2.8 ± 0.22
	C + mGnRH I	73.8 ± 2.51
	C + mGnRH II	81.7 ± 3.12*

25 * p < 0.01 as compared to control

Surprisingly, when added in combination, muGnRH I and II exhibit highly significant increase in GTH release as a result of combination (As shown below in Table 4).

Table 4

Incubations (2µg GnRH fractions)	GtH released (ng/6x10⁴ cells)
Control (C)	2.6 ± 0.18
C + mGnRH I	73.3 ± 2.2[*]
C + mGnRH II	79.2 ± 3.12[*]
C + mGnRH I + mGnRH II	115.0 ± 3.23^{**}
mammalian GnRH	49.9 ± 2.02
salmon GnRH (synthetic)	56.2 ± 2.15
GnRH superactive analogue (des-Gly¹⁰, [D-Ala⁶]-LHRH)	68.0 ± 2.32

Values are mean ± SEM of five experiments.

^{*} p < 0.01 when compared with mammalian or salmon GnRHs

^{**} p < 0.01 as compared with GnRH superactive analogue

In fact, whether alone or in combination, muGnRHs had significantly greater activity as compared to mammalian GnRH, salmon GnRH or the GnRH superactive analogue.

In an embodiment of the present invention addition of calcium to GnRH I and II enhance the gonadotropin releasing activity of GnRH I and II.

Both these synthesized GnRHs showed much greater activity in the laboratory and field experiments as compared to salmon GnRH, its analogues and other superactive analogues and commercial product "Ovaprim". Amino acid sequence of these two decapeptides (murrel GnRH I and II) could not be given here as we have applied for patent. This Indian Product (murrel GnRH I plus II) therefore has great promise for national and international market.

The above mentioned results placed Indian murrel GnRHs (I plus II) as a highly promising global competitor since Salmon GnRH analogue (Ovaprim) prepared by Syndel Laboratory, Canada is dominating the market and extensively sold all over the world to breed culturable fish.

Both the murrel GnRHs (GnRH I and II) are novel, no naturally occurring GnRH discovered till date has such sequences (fig. 7). The activity of the synthetic GnRHs has been examined in the laboratory (pituitary cell culture) and field to breed carps.

A method of inducing breeding in fishes using the said novel gonadotropin releasing hormones said method comprising steps of exposing fishes to the said Gonadotropin-releasing hormones to help release gonadotropin, and inducing breeding in fishes using said gonadotropin.

Claims

1. Two Gonadotropin releasing hormones muGnRH I, and muGnRH II of amino acid sequence QHWSAWRLPG and QHWSWGILPG respectively, useful for induced breeding in fishes both in combination and alone, by activating production of Gonadotropin.
2. The hormones as claimed in claim 1, wherein said hormones are obtained from Indian Murrel brain.
3. The hormones as claimed in claim 1, wherein muGnRH II is a more active gonadotropin-releasing hormone than muGnRH I.
4. The hormones as claimed in claim 1, wherein muGnRH I increase gonadotropin release by about 30 times.
5. The hormones as claimed in claim 1, wherein muGnRH II increase gonadotropin release by about 35 times.
6. The hormones as claimed in claim 1, wherein said hormones show synergy in induced breeding of fishes.
7. The hormones as claimed in claim 1, wherein both muGnRH I, and muGnRH II in combination in the ratio of about 1:1 increase gonadotropin release by about 50 times.
8. The hormones as claimed in claim 1, wherein said hormones show no species barrier in induced breeding of fishes with increase in gonadotropin release ranging between 20-50 times.
9. The hormones as claimed in claim 1, wherein said hormones are more active than other GnRHs comprising mammalian GnRH, Salmon GnRH, GnRH superactive analogues, and commercially available GnRH Ovaprim, both in combination and alone.
10. A method of isolating and sequencing two novel Gonadotropin releasing hormones muGnRH I and muGnRH II of amino acid sequence QHWSAWRLPG and QHWSWGILPG respectively, useful for induced breeding in fishes both in combination and alone, by activating production of Gonadotropin, said method comprising:
 - (a) homogenizing hypothalami in acidic conditions,
 - (b) filtering said homogenate to remove fat and cell debris,
 - (c) adding acetone in a stepwise manner to the said filtrate to obtain three precipitates namely AC I, AC II, and AC III,
 - (d) estimating Gonadotropin Releasing Hormone (GnRH) activity in the precipitates of step (c),

- (e) fractionating only active precipitate AC II further using Molecular Exclusion Chromatography to obtain fractions SG I and SG II,
- (f) estimating Gonadotropin Releasing Hormone (GnRH) activity in the fractions of step (e),
- 5 (g) fractionating only active fraction SG II further, using Ion Exchange Chromatography with anionic column to collect fractions MQ I, MQ II, MQ III, and MQ IV,
- (h) estimating Gonadotropin Releasing Hormone (GnRH) activity in the fractions of step (g), with only fractions MQ I and MQ II having the same,
- 10 (i) fractionating MQ I of step (h) further, using Ion Exchange Chromatography with cationic column to obtain fractions MS I, MS II, MS III, and MS IV,
- (j) estimating Gonadotropin Releasing Hormone (GnRH) activity in the fractions of step (i) with only fraction MS II having the same,
- (k) fractionating MS II fraction using Reverse Phase Chromatography to obtain
- 15 fractions SRP I, SRP II, and SRP III,
- (l) estimating Gonadotropin Releasing Hormone (GnRH) activity in the fractions of step (k) with only fraction SRP II having the same,
- (m) fractionating MQ II of step (h) further, using Reverse Phase Chromatography to obtain fractions QRP I, QRP II, and QRP III,
- 20 (n) calculating Gonadotropin Releasing Hormone (GnRH) activity in the fractions of step (m) with only fraction QRP II having the same, and
- (o) sequencing QRP II and SRP II fractions of steps (n) and (l) and naming them as muGnRH I and muGnRH II respectively.
- 25 11. A method as claimed in claim 10, wherein fraction SG II increase gonadotropin release by about 20 times.
12. A method as claimed in claim 10, wherein fraction SG II increase gonadotropin release by about 20 times.
13. A method as claimed in claim 10, wherein fraction MQ I increase gonadotropin release
- 30 by about 10 times.
14. A method as claimed in claim 10, wherein fraction MQ II increase gonadotropin release by about 40 times.
15. A method as claimed in claim 10, wherein fraction MS II increase gonadotropin release by about 45 times.

16. A method as claimed in claim 10, wherein calcium increases gonadotropin-releasing activity of muGnRH I, and muGnRH II.
17. A method of inducing breeding in fishes using gonadotropin releasing hormones of claim 1, said method comprising steps of exposing fishes to the said Gonadotropin-releasing hormones to help release gonadotropin, and inducing breeding in fishes using
5 said gonadotropin.

1/7

GnRH	1	2	3	4	5	6	7	8	9	10
Mammalian	pGlu-His-Trp-Ser-				<u>Tyr</u> -Gly-Leu-Arg-				Pro-Gly-NH ₂	
Guinea Pig	pGlu- <u>Tyr</u> -Trp-Ser-				Tyr-Gly- <u>Val</u> -Arg-				Pro-Gly-NH ₂	
Chicken I	pGlu-His-Trp-Ser-				Tyr-Gly-Leu- <u>Gln</u> -				Pro-Gly-NH ₂	
Chicken II	pGlu-His-Trp-Ser-				<u>His</u> -Gly- <u>Trp</u> - <u>Tyr</u> -				Pro-Gly-NH ₂	
Salmon	pGlu-His-Trp-Ser-				Tyr-Gly- <u>Trp</u> - <u>Leu</u> -				Pro-Gly-NH ₂	
Lamprey I	pGlu-His- <u>Tyr</u> -Ser-				<u>Leu</u> - <u>Glu</u> - <u>Trp</u> - <u>Lvs</u> -				Pro-Gly-NH ₂	
Lamprey III	pGlu-His-Trp-Ser-				<u>His</u> - <u>Asp</u> - <u>Trp</u> - <u>Lvs</u> -				Pro-Gly-NH ₂	
Tunicate I	pGlu-His-Trp-Ser-				<u>Asp</u> - <u>Tyr</u> - <u>Phe</u> - <u>Lvs</u> -				Pro-Gly-NH ₂	
Tunicate II	pGlu-His-Trp-Ser-				<u>Leu</u> - <u>Cys</u> - <u>His</u> - <u>Ala</u> -				Pro-Gly-NH ₂	
Catfish	pGlu-His-Trp-Ser-				<u>His</u> -Gly-Leu- <u>Asn</u> -				Pro-Gly-NH ₂	
Dogfish	pGlu-His-Trp-Ser-				<u>His</u> -Gly- <u>Trp</u> - <u>Leu</u> -				Pro-Gly-NH ₂	
Sea Bream	pGlu-His-Trp-Ser-				Tyr-Gly-Leu- <u>Ser</u> -				Pro-Gly-NH ₂	
Herring	pGlu-His-Trp-Ser-				<u>His</u> -Gly-Leu- <u>Ser</u> -				Pro-Gly-NH ₂	

Fig. 1 Comparison of primary amino acid sequences of naturally occurring vertebrates and protochordate GnRHs. Underlined amino acids represent differences in forms compared to mammalian GnRH.

2/7




Fig. 2. Hairpin loop of GnRH




Fig 3 Test of murrel GnRH bioactivity in different fractions obtained through acetone fractionation. After preparation of three different acetone fractions, 100µg protein was added *in vitro* pituitary cell culture and release of GH was measured by RIA (as mentioned earlier in materials and methods of this chapter)

4/7




Fig 4. Elution profile of mammalian GnRH through Sephadex G-25 column. AC II fraction was dissolved in 1N acetic acid and eluted through Sephadex G-25 column (58x1.5 cm) at a flow rate of 24 ml/hr.

5/7




Fig. 5'a. Elution profile of murrel Sephadex G-25 P-II through FPLC Mono Q column.

SG-II fraction was dissolved in buffer A - 20mM Tris (pH 8.0) and was injected into the FPLC anion exchange column (Mono Q). At first the column was washed with buffer A and then eluted with buffer B - 20mM Tris (pH 8.0) with 1M NaCl.





Fig. 5'b. Elution profile of murrel Mono Q unbound peak (MQ I) through FPLC Mono S column.

MQ I was dissolved in buffer A - 50mM Ammonium acetate (pH 4.8) and was injected into the FPLC cation exchange column (Mono S). At first the column was washed with buffer A and then eluted with buffer B - 50 mM Ammonium acetate (pH 4.8) with 0.5 M NaCl.

6/7



6. Elution profile of Mono QP-II (a) and Mono SP-II (b) through FPLC Pep-RPC column. GnRH enriched fraction (Mono QP-II) and (Mono SP-II) was dissolved individually in solvent A - 0.1% TFA in water and was injected individually into the FPLC peptide reverse phase chromatography (Pep-RPC). Firstly the column was washed with solvent A and then eluted with solvent B - 0.1% TFA in acetonitrile.

Murrel GnRH I: pGlu-His-Trp-Ser-Ala-Tyr-Arg-Leu-Pro-Gly-NH₂

Murrel GnRH II: pGlu-His-Trp-Ser-Tyr-Gly-Phe-Lys-Pro-Gly-NH₂

Fig. 7. Amino acid sequences of murrel GnRH I and II.

SEQUENCE LISTING

<110> Council of Scientific and Industrial Research

5 <120> Novel two Gonadotropin releasing hormones and a method to isolate
the same

<130> US 855

10 <140> 60/353,041
<141> 2002-01-30

<150> US 60/353,041
<151> 2002-01-30

15 <160> 2

<170> PatentIn version 3.1

20 <210> 1
<211> 10
<212> PRT
<213> channa punctatus

25 <400> 1

Gln His Trp Ser Ala Trp Arg Leu Pro Gly
1 5 10

30 <210> 2
<211> 10
<212> PRT
<213> channa punctatus

35 <400> 2

Gln His Trp Ser Trp Gly Ile Leu Pro Gly
1 5 10

40